Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Bio-Europe SpringBio-Europe Spring
Not Confirmed
Not Confirmed
31 March-01 April, 2026
Nutri Ingredients Summ...Nutri Ingredients Summit
Not Confirmed
Not Confirmed
31 March-01 April, 2026
Not Confirmed
Not Confirmed
01-02 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Bio-Europe Spring
Not Confirmed
Contact SupplierBio-Europe Spring
Bio-Europe SpringBio-Europe Spring
Industry Trade Show
Not Confirmed
31 March-01 April, 2026
Nutri Ingredients Summ...Nutri Ingredients Summit
Industry Trade Show
Not Confirmed
31 March-01 April, 2026
Industry Trade Show
Not Confirmed
01-02 April, 2026
Digital content
NEWS #PharmaBuzz
12 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/12/3255098/0/en/Bolt-Biotherapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html
24 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/24/3243462/0/en/Bolt-Biotherapeutics-to-Participate-in-Upcoming-March-Conferences.html
12 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/12/3186772/0/en/Bolt-Biotherapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html
01 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/01/3159924/0/en/Bolt-Biotherapeutics-Provides-Update-on-BDC-4182-and-Extends-Cash-Runway-into-2027.html
14 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/14/3133839/0/en/Bolt-Biotherapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html
12 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/12/3079551/0/en/Bolt-Biotherapeutics-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Update.html
Drugs in Development
Details:
BDC-4182 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stomach Neoplasms.
Lead Product(s): BDC-4182
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2025
Lead Product(s) : BDC-4182
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BDC-4182 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stomach Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 10, 2025
Details:
The collaboration aims to develop TRK-950, an Caprin-1 designed to target multiple solid tumor types. Currently, it is being evaluated for the treatment of gastric cancer.
Lead Product(s): TRK-950,Paclitaxel,Ramucirumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Toray Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 11, 2025
Lead Product(s) : TRK-950,Paclitaxel,Ramucirumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Toray Industries
Deal Size : Undisclosed
Deal Type : Collaboration
Bolt Biotherapeutics Updates Cancer Immunotherapy Co-Development with Toray
Details : The collaboration aims to develop TRK-950, an Caprin-1 designed to target multiple solid tumor types. Currently, it is being evaluated for the treatment of gastric cancer.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
February 11, 2025
Details:
BDC-1001 is an investigational immune-stimulating antibody conjugate (ISAC), which is being developed for the treatment of patients with HER2-Positive Breast Cancer.
Lead Product(s): Trastuzumab Imbotolimod,Pertuzumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 05, 2023
Lead Product(s) : Trastuzumab Imbotolimod,Pertuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BDC-1001 is an investigational immune-stimulating antibody conjugate (ISAC), which is being developed for the treatment of patients with HER2-Positive Breast Cancer.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
December 05, 2023
Details:
BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid tumors.
Lead Product(s): BDC-3042,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 17, 2023
Lead Product(s) : BDC-3042,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2023
Details:
BDC-1001 is an investigational immune-stimulating antibody conjugate (ISAC), which is being developed for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
Lead Product(s): Trastuzumab Imbotolimod,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 28, 2023
Lead Product(s) : Trastuzumab Imbotolimod,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BDC-1001 is an investigational immune-stimulating antibody conjugate (ISAC), which is being developed for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
September 28, 2023
Details:
BDC-3042 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Triple Negative Breast Neoplasms.
Lead Product(s): BDC-3042
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Regeneron Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 25, 2023
Lead Product(s) : BDC-3042
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BDC-3042 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Triple Negative Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2023
Details:
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist, in development forHER2-positive colorectal, endometrial and gastroesophageal cancers.
Lead Product(s): Trastuzumab Imbotolimod,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 03, 2023
Lead Product(s) : Trastuzumab Imbotolimod,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist, in development forHER2-positive colorectal, endometrial and gast...
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 03, 2023
Details:
BDC-1001 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): BDC-1001
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: F. Hoffmann-La Roche
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 20, 2023
Lead Product(s) : BDC-1001
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Details : BDC-1001 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 20, 2023
Details:
Under the agreement, Roche will provide pertuzumab in support of a Phase 2 metastatic breast cancer trial to evaluate pertuzumab in combination with BDC-1001.
Lead Product(s): Trastuzumab Imbotolimod,Pertuzumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody-drug Conjugate
Sponsor: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 29, 2023
Lead Product(s) : Trastuzumab Imbotolimod,Pertuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Roche will provide pertuzumab in support of a Phase 2 metastatic breast cancer trial to evaluate pertuzumab in combination with BDC-1001.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
March 29, 2023
Details:
BDC-1001 is an investigational immune-stimulating antibody conjugate (ISAC), which is being developed for the treatment of patients with HER2-expressing cancer.
Lead Product(s): Trastuzumab Imbotolimod,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: F. Hoffmann-La Roche
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 29, 2023
Lead Product(s) : Trastuzumab Imbotolimod,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BDC-1001 is an investigational immune-stimulating antibody conjugate (ISAC), which is being developed for the treatment of patients with HER2-expressing cancer.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
March 29, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
